European Medicines Agency concludes action on COX-2 inhibitors
Fri, 01 Jul 2005 06:00 AM EST
... Concluding its review of the class of COX-2 inhibitors, the European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Bextra (valdecoxib) and recommended new contraindications and warnings for other COX-2 inhibitors that continue to be available in the European Union (EU)... click link for more info. ...
Related Topics
- COX-2 Inhibitors
- MAO Inhibitors
- ACE Inhibitors
- Proton-pump Inhibitors
- Black Alder
- Celecoxib
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Rofecoxib
- Over-the-Counter Medicines
- Adoption
- Olanzapine
- Aging
- Persons with Disabilities
- Foster Care
- European Goldenrod
- Rosuvastatin
- Atherosclerosis
- Home Care
- Leuprolide
- Medicines

Not Signed In -


